The role of neuroinflammation in neurodegenerative diseases remains one of the most debated topics in neuroscience. This debate centers on whether chronic neuroinflammation is a primary driver of pathology (causing neuronal dysfunction and death) or a secondary response to other insults (consequence of underlying disease processes). Understanding this distinction has profound implications for therapeutic strategies. [1]
The neuroinflammation-as-cause model proposes that chronic activation of brain immune cells (primarily microglia and astrocytes) initiates or dramatically accelerates neurodegeneration: [2]
Key Supporting Evidence: [3]
The neuroinflammation-as-consequence model argues that neuroinflammation is a protective response that becomes dysregulated secondarily: [4]
Key Supporting Evidence: [5]
| Evidence Type | Supports Cause | Supports Consequence | [6]
|---------------|----------------|---------------------| [7]
| Genetic association | TREM2, CR1, CLU variants | Limited direct evidence | [8]
| Biomarker timing | Some studies show early inflammation | Aβ/Tau changes often first | [9]
| Therapeutic response | Anti-inflammatory failure in trials | — | [10]
| Imaging studies | Microglial activation in preclinical | Correlates with severity | [11]
| Animal models | Inflammatory triggers pathology | Pathology triggers inflammation | [12]
Modern research supports an integrated model where cause and consequence blur:
| Cell Type | Pro-inflammatory | Anti-inflammatory |
|---|---|---|
| microglia | M1 phenotype, TNF-α, IL-1β, IL-6 | M2 phenotype, IL-10, TGF-β |
| astrocytes | A1 phenotype, complement proteins | A2 phenotype, neurotrophic factors |
| neurons | Excitotoxic signals | Anti-inflammatory neuropeptides |
| Approach | Target | Status |
|---|---|---|
| TREM2 agonists | Microglial modulation | Clinical trials ( NCT05415613) |
| Anti-cytokine therapies | IL-1β, TNF-α | Limited success |
| CSF1R inhibitors | Microglial depletion | Preclinical/early clinical |
| NSAID prevention | COX inhibition | Failed in trials |
| Complement inhibition | C1q, C3 | Preclinical |
The neuroinflammation cause vs consequence debate has evolved to recognize the complex, bidirectional relationship between immune activation and neurodegeneration:
The future of neuroinflammation research lies in:
Heneka et al. Neuroinflammation in Alzheimer's disease (2015). 2015. ↩︎
Keren-Shaul et al. Disease-associated microglia (2017). 2017. ↩︎
Kaufman et al. Microglial activation in preclinical AD (2022). 2022. ↩︎
Cai et al. Neuroinflammation as cause and consequence (2023). 2023. ↩︎
Leng & Edison, Neuroinflammation and microglial activation (2021). 2021. ↩︎
Hansen et al. Astrocyte reactivity (2018). 2018. ↩︎
Liddelow et al. Neurotoxic reactive astrocytes (2017). 2017. ↩︎
Michell-Robinson et al. Role of microglia (2015). 2015. ↩︎
Zhang et al. Anti-inflammatory therapy failure in AD (2023). 2023. ↩︎
Van Skike & Galvan, Time-dependent role of inflammation (2018). 2018. ↩︎